SPX3,830.10-1.29 -0.03%
DIA309.74+0.03 0.01%
IXIC11,321.68-0.55 0.00%

BRIEF-Caladrius Biosciences Says Cend Therapeutics Treated First Patient In Phase 2B Trial Of Cend-1

reuters.com · 06/09/2022 08:04
BRIEF-Caladrius Biosciences Says Cend Therapeutics Treated First Patient In Phase 2B Trial Of Cend-1

- Caladrius Biosciences Inc CLBS:

  • CALADRIUS BIOSCIENCES ANNOUNCES MERGER PARTNER, CEND THERAPEUTICS, HAS TREATED FIRST PATIENT IN PHASE 2B TRIAL OF CEND-1 IN COLLABORATION WITH AUSTRALASIAN GASTRO-INTESTINAL CANCER TRIALS GROUP

Source text for Eikon: ID:nGNX8bFVQj

Further company coverage: CLBS


((reuters.briefs@thomsonreuters.com;))